Maravai LifeSciences (MRVI) Projected to Post Quarterly Earnings on Wednesday

Maravai LifeSciences (NASDAQ:MRVI) is projected to release its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Maravai LifeSciences to post earnings of ($0.07) per share and revenue of $49.0610 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 5:00 PM ET.

Maravai LifeSciences Stock Performance

MRVI opened at $2.93 on Wednesday. The company has a quick ratio of 4.56, a current ratio of 5.29 and a debt-to-equity ratio of 0.74. Maravai LifeSciences has a 12-month low of $1.66 and a 12-month high of $4.40. The business has a 50 day moving average of $3.50 and a 200-day moving average of $3.16. The stock has a market cap of $749.23 million, a price-to-earnings ratio of -3.49 and a beta of 0.39.

Analysts Set New Price Targets

Separately, Wells Fargo & Company lifted their price objective on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Maravai LifeSciences currently has an average rating of “Hold” and a consensus target price of $5.25.

Insider Transactions at Maravai LifeSciences

In other news, Director Gregory T. Lucier acquired 48,528 shares of the stock in a transaction on Monday, December 8th. The shares were purchased at an average price of $3.67 per share, for a total transaction of $178,097.76. Following the transaction, the director directly owned 155,123 shares of the company’s stock, valued at approximately $569,301.41. This represents a 45.53% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.11% of the stock is owned by company insiders.

Hedge Funds Weigh In On Maravai LifeSciences

A number of hedge funds have recently bought and sold shares of MRVI. Geode Capital Management LLC boosted its holdings in Maravai LifeSciences by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 2,848,105 shares of the company’s stock valued at $9,259,000 after purchasing an additional 34,447 shares during the period. State Street Corp raised its position in shares of Maravai LifeSciences by 1.1% in the fourth quarter. State Street Corp now owns 2,414,249 shares of the company’s stock valued at $7,846,000 after buying an additional 27,219 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Maravai LifeSciences by 28.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,014,214 shares of the company’s stock valued at $6,546,000 after buying an additional 442,059 shares during the period. Marshall Wace LLP grew its position in Maravai LifeSciences by 52.3% during the fourth quarter. Marshall Wace LLP now owns 2,000,278 shares of the company’s stock worth $6,501,000 after buying an additional 687,253 shares in the last quarter. Finally, Lazard Asset Management LLC grew its position in Maravai LifeSciences by 6.2% during the third quarter. Lazard Asset Management LLC now owns 1,540,226 shares of the company’s stock worth $4,420,000 after buying an additional 89,805 shares in the last quarter. 50.25% of the stock is owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.